Biomarker & Intervention Discovery
Osteoporosis
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs4.08MWHO GHE 2021 · all ages
Global DALYs45.69MWHO GHE 2021 · worldwide
US mortality12.5K deaths/yrWHO GHE 2021
Global mortality110.0K deaths/yrWHO GHE 2021 · worldwide
NIH funding$118MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionBone density decline of 1-3%/year in postmenopausal women without treatment; fracture risk increases exponentially…
Best-intervention remissionBisphosphonates: 40-50% reduction in vertebral fractures, 20-40% hip fracture reduction; romosozumab…
Gap sizeVery large — post-fracture care gap is stark: only 20-30% of patients with fragility fracture receive osteoporosis…
Primary barrierpractice/framing
Full remission profile →
Remission & chronicity
Spontaneous remission
Bone density decline of 1-3%/year in postmenopausal women without treatment; fracture risk increases exponentially with T-score decline; no spontaneous remission
Best-intervention remission
Bisphosphonates: 40-50% reduction in vertebral fractures, 20-40% hip fracture reduction; romosozumab (anti-sclerostin): 73% vertebral fracture reduction at 12 months (ARCH trial); abaloparatide/teriparatide (anabolic): BMD increase 9-12% at lumbar spine over 18 months
Gap size
Very large — post-fracture care gap is stark: only 20-30% of patients with fragility fracture receive osteoporosis treatment within 1 year
Primary barrier
practice/framing
The 'post-fracture care gap' is one of the most documented practice failures in medicine; the majority of fragility fracture patients leave hospital without osteoporosis diagnosis or treatment; fracture liaison services (FLS) fix this but are not universally implemented; anabolic therapies (romosozumab, teriparatide) drastically underused vs anti-resorptives
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Osteoporosis” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."